Get the Stockscreener App
132.18
3.64%
-4.99
Krystal Biotech Inc stock is traded at $132.18, with a volume of 329.79K.
It is down -3.64% in the last 24 hours and down -21.40% over the past month.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
See More
Previous Close:
$137.17
Open:
$139.66
24h Volume:
329.79K
Relative Volume:
1.06
Market Cap:
$4.80B
Revenue:
$290.51M
Net Income/Loss:
$89.16M
P/E Ratio:
44.21
EPS:
2.99
Net Cash Flow:
$119.18M
1W Performance:
-20.45%
1M Performance:
-21.40%
6M Performance:
-33.78%
1Y Performance:
-16.73%
1-Day Range:
$131.71
$140.54
1-Week Range:
$131.71
$167.21
52-Week Range:
$131.71
$219.34
Krystal Biotech Inc Stock (KRYS) Company Profile
Name
Krystal Biotech Inc
Sector
Industry
Phone
(412) 586-5830
Address
2100 WHARTON STREET, PITTSBURGH, PA
Compare KRYS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
132.18 | 4.80B | 290.51M | 89.16M | 119.18M | 2.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-25 | Initiated | Jefferies | Buy |
| Aug-06-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-20-23 | Initiated | Goldman | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-12-23 | Initiated | Citigroup | Buy |
| Sep-07-23 | Initiated | Berenberg | Buy |
| Apr-18-23 | Initiated | Stifel | Buy |
| Feb-28-23 | Upgrade | Goldman | Neutral → Buy |
| Aug-25-22 | Downgrade | Goldman | Buy → Neutral |
| Jan-18-22 | Initiated | BofA Securities | Buy |
| Jul-20-21 | Upgrade | Goldman | Neutral → Buy |
| Sep-18-20 | Initiated | B. Riley FBR | Buy |
| Jun-04-20 | Initiated | Evercore ISI | Outperform |
| Sep-24-19 | Initiated | Goldman | Neutral |
| Aug-06-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-24-19 | Reiterated | Chardan Capital Markets | Buy |
| Jun-24-19 | Reiterated | H.C. Wainwright | Buy |
| May-30-19 | Initiated | Guggenheim | Buy |
| Sep-11-18 | Initiated | Cantor Fitzgerald | Overweight |
View All
Krystal Biotech Inc Stock (KRYS) Latest News
Krystal Biotech, Inc. (KRYS): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Insider Monkey
10 Best Cancer Stocks to Invest in for Long-Term Gains - Insider Monkey
H.C. Wainwright maintains Buy on Krystal Biotech shares - Investing.com Australia
Krystal Biotech, Inc. (KRYS) Misses Q1 Earnings and Revenue Estimates - MSN
Krystal Biotech "insulated" by domestic manufacturingPittsburgh Business Times - The Business Journals
Krystal Biotech (KRYS) Price Target Lowered by Guggenheim | KRYS Stock News - GuruFocus
H.C. Wainwright maintains Buy on Krystal Biotech shares By Investing.com - Investing.com Canada
Krystal Biotech (KRYS) Faces Hurdles After Lowered Price Target | KRYS Stock News - GuruFocus
Krystal Biotech, Inc. (NASDAQ:KRYS) Q1 2025 Earnings Call Transcript - Insider Monkey
Krystal Biotech to Present at BofA Securities 2025 Health Care Conference - The Manila Times
Krystal Biotech Q1 Earnings and Sales Miss Estimates, Stock Down - MSN
Krystal Biotech (KRYS) Maintains Buy Rating and Price Target | KRYS Stock News - GuruFocus
Krystal Biotech Inc (KRYS) Q1 2025 Earnings Call Highlights: Rec - GuruFocus
Krystal Biotech Inc (KRYS) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ... By GuruFocus - Investing.com Canada
Krystal Biotech Reports Strong Q1 2025 Results - TipRanks
Decoding Krystal Biotech Inc (KRYS): A Strategic SWOT Insight - GuruFocus
Krystal Biotech’s Earnings Call Highlights Growth and Expansion - TipRanks
Earnings call transcript: Krystal Biotech misses Q1 2025 EPS forecast, stock drops 14% - Investing.com
Krystal Biotech outlines 2025 global launch strategy with $88.2M Q1 VYJUVEK revenue - MSN
Krystal Biotech (KRYS) Receives Reiterated Buy Rating and Maintained Price Target | KRYS Stock News - GuruFocus
Krystal Biotech Q1 2025 slides: VYJUVEK revenue up 95% YoY despite sequential dip By Investing.com - Investing.com South Africa
Krystal Biotech is Now Oversold (KRYS) - Nasdaq
Krystal Biotech Q1 2025 slides: VYJUVEK revenue up 95% YoY despite sequential dip - Investing.com India
Krystal Biotech shares tumble as Q1 results miss expectations By Investing.com - Investing.com Nigeria
Krystal Biotech Q1 2025 Earnings: EPS of $1.24 and Revenue of $8 - GuruFocus
KRYSTAL BIOTECH Earnings Results: $KRYS Reports Quarterly Earnings - Nasdaq
Krystal Biotech (KRYS) Reports Q1 Revenue Below Expectations Ami - GuruFocus
Krystal Biotech's Q1 Earnings, Revenue Rise - marketscreener.com
Krystal Biotech, Inc. SEC 10-Q Report - TradingView
Krystal Biotech Announces First Quarter 2025 Financial and Operating Results - The Manila Times
Krystal Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Earnings Flash (KRYS) Krystal Biotech Reports Q1 Revenue $88.2M, vs. FactSet Est of $96.2M - marketscreener.com
Krystal Biotech Presents Promising Gene Therapy at ARVO - TipRanks
Krystal Biotech Q1 2025 Earnings Preview - MSN
Krystal Biotech Inc (KRYS) Q1 2025 Earnings Report Preview: What to Look For - GuruFocus
Krystal Biotech (KRYS) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Chardan Capital Forecasts Krystal Biotech FY2025 Earnings - Defense World
Where are the Opportunities in (KRYS) - news.stocktradersdaily.com
Commit To Purchase Krystal Biotech At $150, Earn 16.3% Annualized Using Options - Nasdaq
Krystal Biotech, Inc. (KRYS) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Krystal Biotech shares rise as H.C. Wainwright lifts price target By Investing.com - Investing.com Canada
Krystal Biotech (NASDAQ:KRYS) Given New $240.00 Price Target at HC Wainwright - Defense World
Krystal Biotech’s VYJUVEK gets European approval for DEB treatment - Investing.com
Here's How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years - Benzinga
Krystal Biotech’s VYJUVEK gets European approval for DEB treatment By Investing.com - Investing.com South Africa
Demystifying Krystal Biotech: Insights From 7 Analyst Reviews - Benzinga
Krystal Biotech (KRYS) Price Target Increased to $240 by H.C. Wa - GuruFocus
Krystal Biotech's Vyjuvek gains European approval for rare skin disease treatmentPittsburgh Business Times - The Business Journals
Krystal Biotech gets EU approval for Vyjuvek (KRYS:NASDAQ) - Seeking Alpha
Krystal Biotech Gets EU Approval to Market Treatment for Dystrophic Epidermolysis Bullosa - marketscreener.com
Krystal Biotech Gains EU Approval for VYJUVEK® - TipRanks
Krystal Biotech Inc Stock (KRYS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):